HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICCVAM Recommends Two Animal-Reducing Ocular Irritation Test Methods

This article was originally published in The Rose Sheet

Executive Summary

Two in vitro ocular toxicity test methods for identifying severe irritants have been presented to federal agencies for approval as methods to reduce the number of animals used in testing, the National Toxicology Program's Interagency Coordinating Committee on the Validation of Alternative Methods reports

You may also be interested in...



ICCVAM Successes, Challenges Addressed At Anniversary Symposium

Regulatory acceptance of validated animal alternative tests is the biggest challenge to the work of the Interagency Coordinating Committee on the Validation of Alternative Methods, according to the Personal Care Products Council

ICCVAM Successes, Challenges Addressed At Anniversary Symposium

Regulatory acceptance of validated animal alternative tests is the biggest challenge to the work of the Interagency Coordinating Committee on the Validation of Alternative Methods, according to the Personal Care Products Council

NICEATM Wants Data To Evaluate In Vitro Tests For Nonsevere Ocular Irritants

The National Toxicology Program's Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) is soliciting ocular irritation test data from human, rabbit and in vitro studies to expand its ocular toxicity database and assess the efficacy of four in vitro test methods in identifying nonsevere ocular irritants

Related Content

UsernamePublicRestriction

Register

RS015106

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel